BEACON is a phase II study of the molecule PLN-74809 (bexotegrast) for slowing the progression and reducing the symptoms of idiopathic pulmonary fibrosis.
You may receive the investigational molecule or a placebo. The treatment is administered orally.
To participate, you must have received a diagnosis of idiopathic pulmonary fibrosis.
Clic here to access the official record from the National Library of Medicine for this study
Once the form has been completed and submitted, a member of our team will contact you.
Please note that all information provided is kept confidential in a secure database and will be used for study recruitment purposes only.
This form is protected by reCAPTCHA and Google's Privacy Policy and Terms of Service apply. By completing this form, you consent to share your information in accordance with our Terms of Use et privacy Policy.
